# GPCR (Structure Therapeutics Inc.) - SEC EDGAR Financial Statements

> Structure Therapeutics Inc. reported $1.33B in total assets and a net loss of $293.9M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/GPCR
- Markdown: https://convexityos.com/fundamentals/GPCR.md
- SEC CIK: 0001888886
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:28 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001888886&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$340.4M | Operating profit |
| Net Income | FY 2025 | -$293.9M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$1.34 | Split-adjusted |
| Free Cash Flow | FY 2025 | -$277.3M | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $1.24B | Total debt: $6.83M |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| Research & Development | $225.3M | $108.8M | $70.10M | $36.19M |
| Total Operating Expenses | $176.6M | $158.2M | $102.8M | $52.56M |
| **Operating Income** | -$176.6M | -$158.2M | -$102.8M | -$52.56M |
| **EBITDA** | -$175.2M | -$157.2M | -$102.5M | -$52.28M |
| Income Before Tax | -$140.7M | -$122.2M | -$89.38M | -$51.30M |
| Income Tax Expense | $515K | $310K | $236K | $17K |
| **Net Income** | -$141.2M | -$122.5M | -$89.62M | -$51.32M |
| Basic EPS | -$0.80 | -$0.78 | -$0.81 | -$5.51 |
| **Diluted EPS** | -$0.80 | -$0.78 | -$0.81 | -$5.51 |
| Basic Shares Outstanding | 177.6M | 157.9M | 110.2M | 9.6M |
| Diluted Shares Outstanding | 177.6M | 157.9M | 110.2M | 9.6M |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $134.6M | $100.1M | $66.51M | $68.69M | $58.99M | $54.71M | $42.87M | $33.49M |
| Total Operating Expenses | $156.3M | $118.6M | $89.38M | -$23.99M | $73.79M | $70.45M | $56.31M | $47.06M |
| **Operating Income** | -$156.3M | -$118.6M | -$89.38M | $23.99M | -$73.79M | -$70.45M | -$56.31M | -$47.06M |
| **EBITDA** | -$156.3M | -$118.1M | -$88.80M | $24.40M | -$73.43M | -$70.16M | -$56.04M | -$46.79M |
| Income Before Tax | -$144.6M | -$105.9M | -$75.78M | $33.17M | -$65.60M | -$61.52M | -$46.73M | -$36.34M |
| Income Tax Expense | $171K | $234K | $190K | $170K | $108K | $139K | $98K | $136K |
| **Net Income** | -$144.8M | -$106.2M | -$75.97M | $33.00M | -$65.71M | -$61.66M | -$46.83M | -$36.48M |
| Basic EPS | -$0.66 | -$0.49 | -$0.35 | -- | -$0.37 | -$0.36 | -$0.27 | -- |
| **Diluted EPS** | -$0.66 | -$0.49 | -$0.35 | -- | -$0.37 | -$0.36 | -$0.27 | -- |
| Basic Shares Outstanding | 218.6M | 218.0M | 217.3M | -- | 175.5M | 172.6M | 172.1M | -- |
| Diluted Shares Outstanding | 218.6M | 218.0M | 217.3M | -- | 175.5M | 172.6M | 172.1M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $799.6M | $169.5M | $129.8M | $26.09M |
| Short-Term Investments | $646.6M | $714.0M | $337.5M | $64.75M |
| **Cash & Short-Term Investments** | $1.45B | $883.5M | $467.3M | $90.84M |
| **Total Current Assets** | $1.57B | $891.2M | $473.6M | $93.09M |
| Property, Plant & Equipment, Net | $6.65M | $3.48M | $3.23M | $1.03M |
| Other Non-Current Assets | $717K | $5.11M | $45K | $3.46M |
| **Total Non-Current Assets** | $13.62M | $12.12M | $8.41M | $4.76M |
| **Total Assets** | $1.58B | $903.3M | $482.0M | $97.84M |
| Accounts Payable | $13.86M | $8.02M | $4.74M | $6.01M |
| **Total Current Liabilities** | $63.28M | $36.02M | $24.74M | $13.01M |
| Other Non-Current Liabilities | $647K | $302K | $298K | -- |
| **Total Non-Current Liabilities** | $4.26M | $2.47M | $4.31M | $0 |
| **Total Liabilities** | $67.54M | $38.49M | $29.05M | $13.01M |
| **Total Debt (incl. Leases)** | $6.49M | $3.86M | $5.45M | $260K |
| Common Stock | $21K | $17K | $14K | $1.0K |
| Retained Earnings | -$470.3M | -$329.1M | -$206.6M | -$117.0M |
| Accumulated Other Comp. Income | $1.05M | $914K | $521K | -$110K |
| **Total Stockholders' Equity** | $1.52B | $864.8M | $453.0M | -$115.1M |
| Total Equity | $1.52B | $864.8M | $453.0M | -$115.1M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $222.0M | $272.6M | $316.2M | $799.6M | $102.9M | $147.0M | $152.1M | $169.5M |
| Short-Term Investments | $1.02B | $1.07B | $1.14B | $646.6M | $696.1M | $639.5M | $684.8M | $714.0M |
| **Cash & Short-Term Investments** | $1.24B | $1.34B | $1.46B | $1.45B | $799.0M | $786.5M | $836.9M | $883.5M |
| **Total Current Assets** | $1.28B | $1.37B | $1.49B | $1.57B | $814.0M | $799.3M | $849.6M | $891.2M |
| Property, Plant & Equipment, Net | $10.26M | $6.33M | $6.37M | $6.65M | $4.67M | $3.46M | $3.52M | $3.48M |
| Other Non-Current Assets | $42.45M | $40.99M | $5.55M | $717K | $6.60M | $6.20M | $6.10M | $5.11M |
| **Total Non-Current Assets** | $59.29M | $53.39M | $17.53M | $13.62M | $18.14M | $17.14M | $16.93M | $12.12M |
| **Total Assets** | $1.33B | $1.43B | $1.51B | $1.58B | $832.2M | $816.4M | $866.5M | $903.3M |
| Accounts Payable | $33.88M | $11.13M | $7.82M | $13.86M | $17.80M | $8.99M | $8.71M | $8.02M |
| **Total Current Liabilities** | $107.1M | $66.11M | $56.98M | $63.28M | $57.53M | $39.03M | $36.49M | $36.02M |
| Other Non-Current Liabilities | $1.38M | $1.26M | $863K | $647K | $325K | $317K | $308K | $302K |
| **Total Non-Current Liabilities** | $5.45M | $4.90M | $4.05M | $4.26M | $4.61M | $5.33M | $5.42M | $2.47M |
| **Total Liabilities** | $112.5M | $71.01M | $61.03M | $67.54M | $62.14M | $44.36M | $41.91M | $38.49M |
| **Total Debt (incl. Leases)** | $6.83M | $6.23M | $5.79M | $6.49M | $7.09M | $7.68M | $7.59M | $3.86M |
| Common Stock | $21K | $21K | $21K | $21K | $18K | $17K | $17K | $17K |
| Retained Earnings | -$797.2M | -$652.4M | -$546.3M | -$470.3M | -$503.3M | -$437.6M | -$375.9M | -$329.1M |
| Accumulated Other Comp. Income | -$4.69M | -$3.44M | -$2.19M | $1.05M | $825K | $362K | $815K | $914K |
| **Total Stockholders' Equity** | $1.22B | $1.35B | $1.45B | $1.52B | $770.0M | $772.1M | $824.6M | $864.8M |
| Total Equity | $1.22B | $1.35B | $1.45B | $1.52B | $770.0M | $772.1M | $824.6M | $864.8M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| Net Income | -$141.2M | -$122.5M | -$89.62M | -$51.32M |
| Depreciation & Amortization | $1.33M | $992K | $295K | $277K |
| Stock-Based Compensation | $28.99M | $18.79M | $8.19M | $2.51M |
| Change in Payables | $4.76M | $3.31M | -$860K | $2.15M |
| **Operating Cash Flow** | -$222.2M | -$116.6M | -$79.49M | -$46.12M |
| Capital Expenditure | -$3.61M | -$1.29M | -$2.17M | -$155K |
| **Free Cash Flow** | -$225.8M | -$117.9M | -$81.66M | -$46.27M |
| **Investing Cash Flow** | $89.80M | -$358.9M | -$268.3M | -$62.11M |
| Common Stock Issued | -- | $514.6M | -- | -- |
| **Financing Cash Flow** | $762.5M | $515.3M | $451.5M | $29.01M |
| **Net Change in Cash** | $630.1M | $39.72M | $103.7M | -$79.21M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$144.8M | -$106.2M | -$75.97M | $33.00M | -$65.71M | -$61.66M | -$46.83M | -$36.48M |
| Depreciation & Amortization | $61K | $551K | $576K | $412K | $356K | $291K | $274K | $273K |
| Stock-Based Compensation | $12.73M | $12.63M | $11.64M | $8.07M | $7.50M | $7.51M | $5.92M | $5.83M |
| Change in Payables | $22.75M | $3.31M | -$4.97M | -$5.01M | $8.81M | $280K | $686K | -$423K |
| **Operating Cash Flow** | -$101.7M | -$120.1M | $15.23M | -$64.42M | -$51.00M | -$54.56M | -$52.23M | -$36.47M |
| Capital Expenditure | -$3.65M | $42K | -$1.18M | -$1.50M | -$1.57M | -$232K | -$314K | -$16K |
| **Free Cash Flow** | -$105.3M | -$120.1M | $14.05M | -$65.91M | -$52.57M | -$54.79M | -$52.54M | -$36.48M |
| **Investing Cash Flow** | $50.36M | $74.50M | -$496.9M | $56.14M | -$49.32M | $48.94M | $34.03M | $33.23M |
| **Financing Cash Flow** | $734K | $2.08M | -$1.74M | $705.0M | $56.20M | $517K | $809K | $615K |
| **Net Change in Cash** | -$50.60M | -$43.53M | -$483.5M | $696.7M | -$44.11M | -$5.10M | -$17.39M | -$2.62M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -9.3% | -14.2% | -19.8% | -- |
| Return on Assets (ROA) | -8.9% | -13.6% | -18.6% | -52.5% |
| Current Ratio | 24.81x | 24.74x | 19.14x | 7.16x |
| Quick Ratio | 22.85x | 24.53x | 18.89x | 6.98x |
| Debt to Equity | 0.00x | 0.00x | 0.01x | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -24.1% | -15.9% | -11.8% | -9.3% | -27.4% | -23.2% | -17.4% | -14.2% |
| Return on Assets (ROA) | -22.0% | -15.1% | -11.3% | -8.9% | -25.3% | -21.9% | -16.5% | -13.6% |
| Current Ratio | 11.91x | 20.75x | 26.16x | 24.81x | 14.15x | 20.48x | 23.29x | 24.74x |
| Quick Ratio | 11.58x | 20.31x | 25.59x | 22.85x | 13.89x | 20.15x | 22.94x | 24.53x |
| Debt to Equity | 0.01x | 0.00x | 0.00x | 0.00x | 0.01x | 0.01x | 0.01x | 0.00x |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
